Anavex Life Sciences Corp. (AVXL) |
|
11.66 0.83 (7.66%)
|
08-07 23:24 |
|
Open: |
10.61 |
Pre. Close: |
10.83 |
|
High:
|
11.66 |
Low:
|
10.4 |
|
Volume:
|
928,157 |
Market Cap:
|
903(M) |
|
|
|
|
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.66 - 11.7 |
11.7 - 11.74 |
|
Low:
|
10.29 - 10.34 |
10.34 - 10.38 |
|
Close:
|
11.58 - 11.65 |
11.65 - 11.72 |
|
Technical analysis |
as of: 2022-08-05 4:20:22 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 15.63 One year: 18.26 |
| Support: |
Support1: 11.07 Support2: 9.64 |
| Resistance: |
Resistance1: 13.38 Resistance2: 15.63 |
| Pivot: |
10.87  |
| Moving Average: |
MA(5): 10.64 MA(20): 11.28
MA(100): 10.28 MA(250): 14.04 |
| MACD: |
MACD(12,26): 0 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 36.2 %D(3): 25.1 |
| RSI: |
RSI(14): 57.5 |
| 52-week: |
High: 23.72 Low: 7.13 |
| Average Vol(K): |
3-Month: 947 (K) 10-Days: 723 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AVXL ] has closed below upper band by 12.4%. Bollinger Bands are 33.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 04 Aug 2022
Anavex Life Sciences (AVXL) to Release Quarterly Earnings on Tuesday - MarketBeat
Mon, 01 Aug 2022
AVXL stock gains on the effect of Alzheimer's drug on genes (NASDAQ:AVXL) - Seeking Alpha
Sun, 24 Jul 2022
Anavex Life Sciences Corp. (NASDAQ:AVXL) Shares Acquired by DekaBank Deutsche Girozentrale - Defense World
Fri, 08 Jul 2022
Should You Buy Anavex Life Sciences Corp (AVXL) Stock After it Is Higher By 24.78% in a Week? - InvestorsObserver
Mon, 23 May 2022
Anavex Life Sciences Corp (AVXL) Stock: What Does the Chart Say Monday? - InvestorsObserver
Wed, 11 May 2022
Anavex Life Sciences (AVXL) Q2 2022 Earnings Call Transcript - The Motley Fool
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
77 (M) |
| Shares Float |
75 (M) |
|
% Held by Insiders
|
3 (%) |
|
% Held by Institutions
|
33 (%) |
|
Shares Short
|
8,710 (K) |
|
Shares Short P.Month
|
8,910 (K) |
Stock Financials |
|
EPS
|
-0.58 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.97 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-22.1 |
|
Return on Equity (ttm)
|
-38 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-28 (M) |
|
Levered Free Cash Flow
|
-12 (M) |
Stock Valuations |
|
PE Ratio
|
-20.11 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
5.91 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-31.85 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
